Home Featured Page 137

Featured

Latest

Psilocybin for Cocaine Use Disorder: Peter Hendricks on a Trial Ten Years in the Making

Pα+ Psychedelic Bulletin #224: Reactions to Trump’s Psychedelics Executive Order, and What Comes Next; Pre-EO, DEA Poured Cold Water on Right to Try

God, Gabon, and Government: W. Bryan Hubbard on Ibogaine, the Executive Order, and What Comes Next

The Optimisation Problem: What Bryan Johnson’s 5-MeO-DMT Experiment Reveals About Psychedelics Going Mainstream

Martha Hammel and Tasia Poinsatte – Aspen Psychedelic Symposium

Israeli Based Biotech Company Clearmind Medicine Inc’s CEO, Dr. Adi Zuloff-Shani,...

Psychedelics Weekly – Proposition 122 in Action, The Economics of Psychedelics,...

FILAMENT HEALTH AND PSYENCE ANNOUNCE WORLDWIDE LICENSING AGREEMENT OF PSILOCYBIN CAPSULE...

PsyBio Therapeutics Takes Initial Step to Help Protect the Sonoran Desert...

MIND CURE ENTERS INTO BINDING LETTER OF INTENT WITH LNG ENERGY...

Braxia Scientific Reports Q2 2023 Financial Results; Focused on Growing Clinic...

Psyence Group Announces Closing of Second Tranche of Private Placement and...

Silo Pharma Issues Letter to Shareholders Detailing Progress on Pipeline Assets...

Algernon Pharmaceuticals Receives U.S. FDA Orphan Drug Designation for Ifenprodil for...

Ehave Shareholder from CEO Ben Kaplan and Corporate Update

EDITOR PICKS

Psilocybin for Cocaine Use Disorder: Peter Hendricks on a Trial Ten...

Pα+ Psychedelic Bulletin #224: Reactions to Trump’s Psychedelics Executive Order, and...

God, Gabon, and Government: W. Bryan Hubbard on Ibogaine, the Executive...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.